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Background: Airway anastomotic complications are a leading cause of mortality after lung transplantation. 
Among the factors that cause airway complications, preoperative steroid use has been considered to be re-
lated with postoperative airway healing. We analyzed the influence of preoperative steroid use on post-
operative airway complications. Methods: The medical records of 66 double-lung transplant recipients from 
January 2014 to December 2015 were reviewed. Forty patients were prescribed steroids preoperatively. The 
daily steroid dose was standardized using the patient’s body mass index (BMI). Patients who received pre-
operative steroids were sub-divided into high-dose (HD) and low-dose (LD) groups (cut-off value, 1.6 
mg/BMI/day). Results: Thirteen patients suffered from airway complications postoperatively (bronchopulmo-
nary fistula, 9; bronchial stenosis, 4). There was a tendency for early development of airway complications in 
the steroid use group compared to the non-steroid use group, but it was not significant (percentage free 
from airway complications in year 1: non-steroid group, 90.9% vs. steroid group, 79.2%; p=0.43). The per-
centage of patients in the LD and HD groups who were free from airway complications in year 1 was not 
significantly different (84.0% vs. 77.8%, p=0.39). Conclusion: The airway complication rate did not vary sig-
nificantly according to steroid use. Additionally, in patients who received preoperative steroids, the dose did 
not affect the rate of development of airway complications.
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Introduction
Lung transplantation is the only viable treatment 
option for end-stage lung disease. The postoperative 
course and outcomes have gradually improved over 
the last few decades due to advances in surgical 
techniques and the development of immunosuppres-
sants. However, critical complications can still occur, 
such as inadequate airway healing, infection, and 
rejection. Many patients with end-stage lung disease 
are prescribed corticosteroids to resolve inflamma-
tion. Preoperative steroid use has been considered to 
contribute to several postoperative complications, in-
cluding poor bronchial anastomosis healing [1,2]. The 
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Table 1. Baseline characteristics of patients according to whether they received steroids preoperatively
Characteristic
Total 
(n=66)
Preoperative steroid 
(n=40)
No steroid 
(n=26)
p-value
Age (yr) 50.8±14.7 50.2±15.0 51.6±14.4 0.70
Sex 0.74
Male 39 (59.1) 17 (42.5) 16 (61.5)
Female 27 (40.9) 23 (57.5) 10 (38.5)
Total follow-up duration (mo) 29.5±20.8 26.8±18.2 33.7±24.0 0.19
Disease entity 0.61
Pulmonary fibrosis 43 (65.2) 27 (67.5) 16 (61.5)
Organizing pneumonia 14 (21.2) 11 (27.5) 3 (11.5)
Lymphangioleiomyomatosis 2 (3.0) 0 2 (7.7)
Bronchiectasis 5 (7.6) 2 (3.0) 3 (11.5)
Primary pulmonary hypertension 2 (3.0) 0 2 (7.7)
Preoperative forced expiratory volume in 1 second 1.70±0.55 1.63±0.56 1.81±0.54 0.45
Airway complication 13 (19.7) 9 (22.5) 4 (14.3) 0.47
Bronchopulmonary fistula 9 (13.6) 6 (15.0) 3 (11.5)
Bronchial stenosis 4 (6.1) 3 (7.5) 1 (3.8)
Length of stay (day) 75.7±79.8 83.8±88.2 62.7±63.5 0.30
Intensive care unit stay (day) 23.7±32.4 23.5±30.2 24.1±36.2 0.95
Values are presented as mean±standard deviation or number (%).
reduction or discontinuation of high doses of cortico-
steroids is recommended before lung transplantation 
at most centers [3].
Previous international guidelines for the selection 
of lung transplantation candidates suggested that 
preoperative prednisone use was a contraindication 
for lung transplantation [2]. Other international 
guidelines for the selection of lung transplant candi-
dates recommended making attempts to discontinue 
preoperative corticosteroids or at least to reduce the 
dose to ≤20 mg per day [4]. The debate about ste-
roid dosing before lung transplantation is still 
ongoing. Several studies found no adverse effects of 
preoperative steroid use on survival, and a few studies 
reported that low doses of steroids (＜0.3 mg/kg/day) 
could have a positive effect on bronchial stenosis 
[5,6]. Nevertheless, many centers still decrease or 
discontinue prednisone use before lung trans-
plantation despite the limited evidence regarding the 
optimal preoperative dosing of steroids. In the field 
of transplantation, body mass index (BMI) has been 
repeatedly reported to affect the dose of im-
munosuppressive drugs, including prednisone [7].
The aim of this study was to evaluate the influ-
ence of preoperative steroid use on airway compli-
cations.
Methods
For this retrospective analysis, we reviewed our 
transplantation database and electronic medical 
records. Between January 2014 and December 2015, 
a total of 66 patients underwent double-lung trans-
plantation, of whom 40 patients were prescribed ste-
roids preoperatively and 26 were not. We defined 
preoperative steroid use as the use of steroids within 
1 month prior to the transplantation. To standardize 
each patient’s daily dose of steroids, the preoperative 
steroid dose was converted to the corresponding 
dose of prednisolone and divided by the patient’s 
BMI. After ranking the quotients from lowest to high-
est, a mean result was obtained (prednisolone, 1.6 
mg/BMI/day; range, 0.2 to 6.9 mg/BMI/day). Patients 
were divided into high-dose (HD) and low-dose (LD) 
groups. Patients with a daily prednisolone dose high-
er than 1.6 mg/BMI/day were assigned to the HD 
group (n=11). The other 29 patients who received 
＜1.6 mg/BMI/day of prednisolone were assigned to 
the LD group. The median daily prednisolone dose in 
the HD group was 171.7 mg/day (range, 40.0 to 
1,000 mg per day) and that in the LD group was 
12.8 mg/day (range, 3.0 to 30.0 mg per day).
The induction and maintenance of immunosup-
pression were similar in all patients. Our postopera-
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Table 2. Comparison between high-dose and low-dose groups among patients who received steroids preoperatively
Variable Low dose (n=29) High dose (n=11) p-value
Disease entity 0.54
Pulmonary fibrosis 20 (68.0) 7 (63.6)
Organizing pneumonia 7 (24.1) 4 (36.4)
Bronchiectasis 2 (6.9) 0
Prednisolone dose (mg/BMI/day) 12.8 (3.0–30.0) 171.0 (40.0–1,000.0) 0.004
BMI (kg/m2) 21.1±3.9 20.2±4.3 0.49
Prednisolone dose (mg/BMI) 0.6±0.4 4.3±2.6 0.001
Intensive care unit stay (day) 23.9±32.4 22.5±7.5 0.67
Length of hospital stay (day) 62.7±46.4 97.8±113.0 0.01
Airway complication 6 (24.0) 3 (27.3) 0.65
Bronchopulmonary fistula 4 (16.0) 2 (18.2)
Bronchial stenosis 2 (8.0) 1 (9.1)
Values are presented as number (%), median (range), or mean±standard deviation.
BMI, body mass index.
tive immunosuppressive protocol was performed ac-
cording to the triple immunosuppressive regimen, in-
cluding tacrolimus, mycophenolate mofetil, and ste-
roids [8]. Methylprednisolone (500 mg, intravenous 
[IV]) was administered just before reperfusion of the 
transplanted lungs, and its administration was con-
tinued to the third postoperative day at 0.5 mg/kg/day. 
On the fourth postoperative day, IV methylpredniso-
lone was switched to oral prednisolone at 0.5 
mg/kg/day. The daily dose of prednisolone was grad-
ually tapered to 0.25 mg/kg/day. Tacrolimus admin-
istration started on the day of the operation. The 
dose was adjusted to maintain a serum level of 8 to 
12 ng/mL. Mycophenolate mofetil was administered 
at 1,000 mg/day routinely, unless leukocytopenia 
occurred.
The operative technique and the initial post-
operative care after lung transplantation followed 
routine procedural steps. Bronchial anastomosis was 
performed using the end-to-end method approx-
imately 1 ring above the donor second carina. A run-
ning 4-0 polydioxanone suture was used for the 
membranous portion, while multiple interrupted 4-0 
polydioxanone sutures were used for the cartilage 
portion [9]. The anastomosis site was wrapped with 
pericardial tissue using a Vicryl 4-0 suture to main-
tain its integrity.
Airway complications, such as bronchopulmonary 
fistula and bronchial stenosis, were confirmed from 
bronchoscopy findings. We defined bronchopulmo-
nary fistula as the presence of air bubbles at the 
anastomosis site after a saline injection test using 
bronchoscopy. Bronchial stenosis was defined as the 
presence of granulation tissue or fibrosis in the air-
way lumen at the site of the airway anastomosis.
All data were collected retrospectively. General 
demographic data and postoperative variables were 
expressed as the mean±standard deviation, median 
(range), or as percentages. Comparisons between 
groups were performed using the chi-square and 
Fisher exact tests as appropriate. Survival curves 
were generated by Kaplan-Meier analysis and were 
compared by log-rank analysis. All p-values ＜0.05 
were considered to indicate statistical significance. 
Statistical analyses were performed with IBM SPSS 
for Windows ver. 23.0 (IBM Corp., Armonk, NY, USA).
This study was approved by the Institutional 
Review Board of Yonsei University (IRB approval no., 
4-2018-0958), and patient consent was waived. 
Results
The mean age of the 66 transplant patients was 
50.8±14.7 years. All of them underwent bilateral lung 
transplantation. Fifty-nine percent of the transplant 
recipients were males. The mean follow-up duration 
was 29.5±20.8 months. Table 1 presents the demo-
graphic profile of the patients. The disease entities 
were not significantly different between the steroid 
group and the non-steroid group (p=0.61). The most 
common disease in both groups was pulmonary fib-
rosis (n=43, 65.2%). The duration of time spent in 
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Fig. 1. Freedom from airway complications in the (A) steroid versus non-steroid groups, (B) and the high-dose versus low-dose groups.
the intensive care unit and the length of the post- 
transplantation follow-up interval were comparable. 
However, the length of hospital stay was slightly lon-
ger in the steroid group, although the difference was 
not statistically significant (83.8±88.2 days versus 
62.7±63.5 days, p=0.30). The preoperative forced ex-
piratory volume in 1 second did not show a statisti-
cally significant difference between the groups (p= 
0.45).
Within the preoperative steroid group, the patients 
were sub-divided into HD and LD groups. There 
were no significant differences in the disease entities 
between these groups (Table 2). A total of 13 pa-
tients (19.7%) experienced airway complications 
postoperatively. Six of these patients belonged to the 
LD group. Of those 6 patients, 2 developed right 
bronchial stenosis at a site distal to the anastomosis 
site. After several balloon dilation procedures, they 
recovered. The remaining 4 developed broncho-
pleural fistula. They all died from sepsis during the 
first postoperative year. Three patients in the HD 
group experienced airway complications. Two of 
them suffered bronchial stenosis. One of these 2 pa-
tients recovered after 2 balloon dilation procedures, 
while the other died on postoperative day 49 due to 
ventricular fibrillation. One patient in the HD group 
developed bronchopleural fistula. He died due to sep-
sis on postoperative day 56.
No statistically significant difference was found in 
the incidence of airway complications between the 
non-steroid and preoperative steroid groups, al-
though there was a tendency for the early develop-
ment of airway complications in the preoperative ste-
roid group (percentage free from airway complica-
tions in year 1: non-steroid group, 90.9% versus ste-
roid group, 79.2%; p=0.43) (Fig. 1A). Within the ste-
roid-use sub-groups, there was no significant differ-
ence in the airway complication rate during fol-
low-up according to dosage (percentage free from 
airway complications in year 1: LD group, 84.0% ver-
sus HD group, 77.8%; p=0.39) (Fig. 1B).
Discussion
Airway complications are among the leading causes 
of morbidity after lung transplantation. These compli-
cations continue to occur despite advances in oper-
ative techniques and perfusion preservation [6].
Several factors play a role in the etiology of air-
way complications. It was believed that perioperative 
steroid therapy might have a negative effect on bron-
chial anastomosis healing [10]. However, the use of 
corticosteroids for end-stage lung disease is common. 
Up to 66% of patients on the waiting list for lung 
transplantation have received preoperative corticoste-
roids. Preoperative corticosteroid therapy was ini-
tially considered an absolute contraindication to lung 
transplantation [2]. However, recent evidence has 
demonstrated that the previously reported negative 
effects of corticosteroids are equivocal [3,5]. A few 
clinical studies reported the possibility of normal 
bronchial healing despite the administration of corti-
costeroids [11]. From recent studies, it seems clear 
that a small to moderate dose of corticosteroids dur-
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ing the pre-transplant period does not adversely af-
fect the postoperative outcome [5,12]. Moreover, 
some studies reported that patients on low doses of 
prednisolone (＜0.42 mg/kg/m2) had better survival 
outcomes than those on high doses [3,5,10]. In this 
study population, the daily prednisolone dosage 
ranged from 3.0 to 1,000.0 mg. We used the BMI to 
standardize the optimal dose of steroids. The doses 
ranged from 0.2 to 6.9 mg/BMI/day. Sub-group anal-
yses were performed to compare patients who re-
ceived high and low doses. The median dosage was 
1.6 mg/BMI/day.
In this study, regardless of the preoperative diag-
nosis and irrespective of when the patient underwent 
lung transplantation, the airway complication rate 
was not significantly different between the steroid 
and non-steroid groups. Sub-group analyses compar-
ing the HD group with the LD group also revealed 
no statistically significant differences in terms of air-
way complications. However, although these findings 
were not statistically significant, our results showed 
a higher tendency for airway complications in the 
HD group during the first postoperative year. The 
possibility that the outcome of patients who received 
high doses of corticosteroids was poorer in the early 
postoperative period cannot be ignored. To de-
termine the effect of low doses of corticosteroids, we 
additionally performed sub-group analyses of the 
non-steroid group and the LD group (data not 
shown). No significant differences in airway compli-
cations were found between these groups.
As is well known, bronchial dehiscence is a dis-
astrous complication that occurs during the post-
operative period in transplant recipients. Most cases 
involving bronchial dehiscence resulted in death due 
to sepsis. Bronchial dehiscence occurs early after 
lung transplantation and is difficult to treat. Bronchial 
stenosis is the most frequent complication after lung 
transplantation. Mechanical obstruction due to in-
grown granulation tissue can be managed with rigid 
bronchoscopy by the removal of additional tissue and 
the insertion of silicone or an expendable stent. If 
this procedure fails, surgical resection of the ob-
structed portion can be considered [13]. In our co-
hort, 4 patients experienced bronchial stenosis after 
transplantation. Their conditions were successfully 
reversed after several balloon dilation procedures.
As in the present study, many recent studies found 
no correlation between pre-transplantation steroid 
use and early outcomes, especially airway complica-
tions. The results of this study provide further sup-
port for the acceptability of preoperative steroid use 
in patients on the lung transplant waitlist. However, 
the optimal dosage still remains uncertain. The low-
est preoperative steroid dose in the HD group of this 
study was 40 mg/day or 1.75 mg/BMI/day, and the 
median preoperative steroid dose was 1.6 mg/BMI/day. 
Although there was no statistically significant differ-
ence in airway complications between the LD and 
HD groups, there seemed to be a trend for a higher 
airway complication rate in the HD group. Therefore, 
it is important to personalize the preoperative ste-
roid dose and to limit the dosage in order to im-
prove the early postoperative course.
In conclusion, preoperative corticosteroid use did 
not seem to affect the occurrence of airway compli-
cations after lung transplantation. Therefore, the use 
of corticosteroids should not be considered a contra-
indication for lung transplantation. However, the air-
ways of patients who receive high doses of steroids 
must be carefully monitored during the early fol-
low-up period.
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